Abstract
The KRAS(G12D) mutation, frequently found in pancreatic cancer, is representative of various challenging cancers and is a crucial target for chemotherapy drug development. Researchers are exploring highly selective and potent small molecule inhibitors of KRAS(G12D) to meet the needs of patients with this mutation. The Patent Highlight reveals novel compounds capable of inhibiting KRAS(G12D) proteins, potentially useful in treating KRAS(G12D)-associated diseases, including cancers.